Palatin Technologies (Palatin Technologies) Tax Provision

: $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

Palatin Technologies's tax provision for the three months ended in Dec. 2023 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Palatin Technologies Tax Provision Historical Data

The historical data trend for Palatin Technologies's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Tax Provision

4.68

Palatin Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Tax Provision																4.68	-	-	-	-

Palatin Technologies Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Palatin Technologies (Palatin Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (AMEX:PTN) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

PTN:Germany PTN:Germany

Address

4B Cedar Brook Drive, Cranbury, NJ, USA, 08512

Website

https://www.palatin.com

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Executives

Stephen T Wills	officer: Executive Vice President, CFO	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Alan W Dunton	director	VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406
Carl Spana	director, officer: President and CEO	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Deveer Robert K Jr	director	C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Joseph Stanley Hull	director	PALATIN TECHNOLOGIES INCORPORATED, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Arlene Morris	director	C/O AFFYMAX, INC., 4001 MIRANDA AVE., PALO ALTO CA 94304
Anthony M. Manning	director	C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Angela Rossetti	director	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Robert I Taber	director	C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Zola P Horovitz	director	C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Perry B Molinoff	director, officer: Exec. VP Research and Devel.	C/O PALATIN TECHNOLOGIES INC, 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104